Which treatment fits which knee problem

A focal knee cartilage defect leaves patients facing a spectrum of options, and two in particular sit at very different ends of the intervention scale: a ChondroFiller injection delivered under ultrasound guidance in an outpatient clinic, and OATS (Osteochondral Autograft Transfer), a surgical procedure performed under general anaesthetic in an operating theatre. Understanding which fits which problem is the first practical step.

The clearest dividing line is how deep the damage goes. ChondroFiller injection is suited to focal chondral defects — surface-layer cartilage damage where the bone beneath remains largely intact. OATS addresses osteochondral defects, where both the cartilage surface and the underlying subchondral bone are involved; the procedure transplants bone and cartilage together as a single unit. Both approaches are aimed at the same broad patient profile: younger or middle-aged, active individuals with a contained, focal lesion rather than the widespread joint deterioration seen in advanced osteoarthritis.

The two treatments are not always alternatives. In some cases they are used at different points in the same patient's care — an injection pathway first, surgery later, or ChondroFiller top-up injections used to protect remaining cartilage after an OATS procedure. The sections below set out the detail behind each option.

How each treatment repairs the cartilage

The two treatments work through fundamentally different biological processes — one invites the body to rebuild cartilage from within a scaffold; the other moves ready-formed cartilage from one part of the knee to another.

ChondroFiller injection: matrix-induced chondrogenesis

Once injected under ultrasound guidance, the ChondroFiller collagen gel sets within minutes at body temperature, filling the defect and conforming to its shape. The scaffold is acellular — no donor cells are introduced alongside it. Instead, the type I collagen matrix acts as a three-dimensional framework into which the patient's own progenitor cells migrate from the surrounding tissue. Over the following months, those cells populate the scaffold and produce repair cartilage through a process called matrix-induced chondrogenesis. Because healing depends on the patient's own biological response, individual cell-repopulation capacity plays a role in outcome — the scaffold provides the structure, but the body does the regenerative work.

OATS: transplanting intact hyaline cartilage

OATS works on an entirely different principle. The surgeon cores out one or more cylindrical plugs — each comprising a surface layer of native hyaline cartilage bonded to the subchondral bone beneath it — from a low-load zone of the same knee. Those plugs are press-fitted directly into the prepared defect site. The bone component integrates into the host subchondral bone, anchoring each plug structurally, while the cartilage surface is restored immediately with pre-formed hyaline cartilage rather than repair tissue grown over time.

Hyaline cartilage — the type that lines healthy knee joints — is more durable than the fibrocartilage produced by older marrow-stimulation techniques such as microfracture, and is structurally superior to scaffold-regenerated repair tissue in long-term load-bearing terms. The trade-off is that harvesting plugs creates a secondary defect at the donor site within the same knee, a consideration that does not arise with the injection pathway.

Neither treatment involves joint replacement; both aim to restore the native knee surface and preserve the joint.

What the procedure involves on the day

ChondroFiller injection

The appointment takes 30 to 45 minutes and requires no operating theatre. Under real-time ultrasound guidance, the clinician locates the defect and injects the collagen scaffold directly into it; no incision is made and no general anaesthetic is given. Intravenous antibiotic cover is used as a precaution. The scaffold sets within the defect in minutes, and the patient leaves the clinic the same day.

Ultrasound guidance is the enabling technology here — accurate needle placement within the defect is what allows the scaffold to settle precisely where it is needed. Because image-guided delivery accuracy matters to outcome, it is worth asking a prospective clinic how many ChondroFiller injections the named clinician has personally performed before booking.

OATS

OATS takes place in a surgical theatre under general anaesthetic, with a theatre time of typically 90 minutes to two hours. The surgeon harvests one or more osteochondral plugs from the low-load zone of the same knee and press-fits them into the prepared defect site within the same session — harvest and implantation happen in a single surgical episode, with no second operation needed for implantation. Depending on case complexity, the patient may be discharged the same day or require an overnight stay.

In that respect the two approaches share one feature: neither requires a return to theatre for a second-stage procedure, which sets both apart from cell-based techniques such as ACI or MACI. The practical difference lies not in the number of stages but in what each single stage demands — a clinic appointment on one hand, a surgical admission with general anaesthesia on the other.

Patient selection: defect size, depth, and eligibility

Defect depth is the first filter. ChondroFiller injection is suited to surface chondral lesions — defects that erode the cartilage layer itself but leave the subchondral bone beneath broadly intact. OATS, by contrast, can address osteochondral lesions extending into bone, because each plug carries its own subchondral bone component and integrates at the bony level rather than relying on an intact recipient plate.

Defect size

Coverage area is the second criterion. ChondroFiller injection typically provides scaffold coverage of up to approximately 3 cm² per box; where a defect is larger or involves more than one area, two or three boxes can extend treatable coverage to around 6 cm². No upper age ceiling applies to the injection pathway. OATS, using a single plug, is most reliably indicated for focal, contained lesions of 1–2 cm². Mosaicplasty — the multi-plug variant — can address up to approximately 4 cm², though surface congruity becomes more technically demanding as the plug count rises. Critically, the defect must sit in a surgically accessible load-bearing zone, and the patient must have sufficient healthy cartilage and bone at a low-load harvest site within the same knee. When donor tissue is inadequate — because of prior surgery, diffuse disease, or unfavourable anatomy — OATS is not feasible regardless of defect dimensions.

Prior treatment history

Patients who have already undergone marrow-stimulation procedures such as microfracture without lasting benefit face a clinically specific consideration. Evidence indicates that microfracture can cause damage to the subchondral bone plate over time — and that damage is directly relevant to both pathways: OATS plug integration depends on viable host bone at the recipient site, while ChondroFiller injection is best suited to lesions in which the subchondral plate remains substantially intact. A history of failed microfracture is therefore not merely a prompt to try an alternative — it shapes which scaffold or transplant option is anatomically appropriate and warrants dedicated MRI assessment, ideally including cartilage-specific sequences, before any further treatment decision is made.

Cost, recovery, and practical differences

Cost separates the two treatments more clearly than almost any other practical variable. The ChondroFiller injection starts at £3,000 for a single box and rises to £5,500 (two boxes) or £8,000 (three boxes), each price inclusive of consultation, ultrasound, the product itself, IV antibiotic cover, and a six-week follow-up appointment. OATS is priced at approximately £14,000 all-inclusive — covering theatre fees, consultant surgeon, anaesthetist, and a twelve-month follow-up — positioning it between standard cartilage repair procedures (from around £9,800) and osteochondral allograft replacement with donor tissue (approximately £28,000). Neither pathway is routinely NHS-funded for this indication; both are typically accessed privately.

The difference in cost reflects a genuine difference in what each procedure demands rather than a difference in quality of intent. A 30–45 minute outpatient appointment with no theatre, no anaesthetist, and no surgical team has fundamentally lower overhead than a 90-minute to two-hour surgical admission under general anaesthetic.

Recovery

Recovery timelines follow the same logic. The ChondroFiller injection pathway involves no surgical wound and no anaesthetic recovery period; patients generally resume weight-bearing and daily activity earlier than after any operative procedure. OATS requires a standard post-surgical rehabilitation course with an initial period of protected weight-bearing, and return to sport is typically measured in months.

Evidence base

OATS carries a longer published follow-up record. The evidence base for ChondroFiller injection durability is still maturing, with fewer long-term series available. No randomised controlled trial has directly compared the two approaches, so outcome comparisons remain inferential rather than head-to-head. Both techniques show clinical and imaging evidence of benefit in appropriate patients; the choice turns on the patient's defect characteristics, surgical suitability, and practical circumstances rather than on a definitive comparative trial.

Can ChondroFiller injection and OATS work together

Rather than competing, the two approaches sometimes follow one another. The post-OATS care programme at London Cartilage Clinic includes annual MRI surveillance alongside preventative ChondroFiller injections every two years — used not to address the transplant site itself, but to support the broader cartilage environment remaining in the joint. This sequencing illustrates that a surgical transplant and an ultrasound-guided injectable scaffold can serve complementary roles across a patient's treatment timeline, not rival ones.

In earlier stages of disease, ChondroFiller injection may also be the appropriate starting point for patients with wider or more diffuse surface involvement — offering scaffold support while the joint is monitored before any surgical decision is made.

The practical implication is that for some patients this is not a permanent either/or choice. Treatment may begin with the least invasive option suited to current imaging findings and evolve as the clinical picture develops — a staged approach consistent with joint-preservation principles across the cartilage-repair specialty.

Patients in Lincolnshire can access a consultant-led knee assessment without a GP referral through Lincolnshire Knee, part of the MSK Doctors group, at Sleaford NG34 or Grantham NG31.

1. [1] Articular cartilage stem cell paste grafting. https://en.wikipedia.org/?curid=36740925 https://en.wikipedia.org/?curid=36740925
2. [2] Articular cartilage repair. https://en.wikipedia.org/?curid=19042351 https://en.wikipedia.org/?curid=19042351